ONCOSEC MEDICAL Inc ONCS Cash Flow

Oncosec medical inc (ONCS)

CashFlow / Quarterly

Jan'20	Oct'19	Jul'19	Apr'19	Jan'19	Oct'18	Jul'18	Apr'18	Jan'18	Oct'17	Jul'17	Apr'17	Jan'17	Oct'16	Jul'16	Apr'16	Jan'16	Oct'15	Jul'15	Apr'15	Jan'15	Oct'14
Operating activities
Net loss
-13,634	-9,760	-7,502	-6,883	-8,315	-7,575	-12,439	-10,060	-10,736	-5,900	-5,897	-4,560	-5,387	-5,603	-6,561	-6,251	-7,037	-7,037	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,987	-4,618	-4,061
Depreciation and amortization
55	56	60	61	60	60	61	82	94	96	95	95	94	94	101	102	86	65	62	170	220	211
Amortization of right-of-use asset
191	169	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-161	0	-41	-0	-	-	-	-
Amortization of discount on investments
-	-	1	7	14	28	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
1,366	574	376	684	912	1,391	2,347	2,923	2,426	554	637	782	1,448	1,148	-	-	-	-	-	-	-	-
Common stock issued for services
247	202	-	-	205	239	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued for services
-	-	-	-	-	-	402	600	734	109	0	0	0	0	-	-	-	-	-	-	-	-
Modification of equity award
-	-	0	0	0	135	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency exchange loss, net
144	3	95	77	-63	171	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2
Stock-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,562	897	633	405	611
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-	-	-	-	-	-	-	590	451	-142	-185	193	-67	189	-322	-218	128	-441	518	386	194	-30
Prepaid expenses and other current assets
-733	345	-	-	-186	526	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-58	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term assets
-43	0	0	0	11	-3	-2	48	11	-7	-75	0	162	0	0	0	0	-26	-	-	-	-
Accounts payable and accrued liabilities
3,926	1,295	330	-454	299	-917	2,005	268	-601	-245	370	-652	256	-183	400	-638	550	549	602	284	370	-188
Accrued compensation related
-231	-36	-	-	601	416	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities
-284	-290	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued compensation related
-	-	-	-	-	-	710	199	-47	93	-53	51	-192	66	-274	-88	104	0	-	-	-	-
Other long-term liabilities
-	-	-116	-259	-310	-150	312	-18	33	4	-55	3	63	242	281	281	558	-265	-	-	-	-
Net cash used in operating activities
-7,440	-8,131	-8,092	-7,683	-6,449	-6,778	-6,221	-5,785	-6,134	-5,079	-	-	-	-	-	-	-	-	-	-	-	-
Investing activities
Decrease in accrued other and taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-35
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-3,812	-4,424	-4,068	-4,730	-4,357	-4,657	-5,222	-5,061	-3,937	-3,429
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	-	11	0	0	9	314	95	579	481	650	198	130	433
Maturity of investment securities
-	-	1,000	3,250	5,232	7,754	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Sale of investment securities
-	-	0	0	0	5,977	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	1,000	3,240	5,232	13,731	-3	-23,277	-8	0	-	-	-	-	-	-	-	-	-	-	-	-
Financing activities
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-9	-394	-95	-579	-481	-669	-198	-130	-433
Proceeds from issuance of common stock through ESPP
-	-	3	0	10	12	0	16	0	19	0	-25	-0	25	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock and/or warrants
-	-	10,377	2,519	7,000	8,000	0	23,000	0	9,283	-44	44	0	0	-	-	-	-	-	-	-	-
Payment of financing and offering costs
-	-	314	271	333	240	-1	2,180	388	1,008	15	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercise of options
-	-	0	0	26	539	94	68	157	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
-	-	-	-	-	-	0	406	9,584	9	-30	14	3	13	6	0	0	0	-	-	-	-
Principal payments on note payable
21	62	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax withholdings paid on equity awards
7	8	15	35	35	15	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Tax withholdings paid related to net share settlement of equity awards
-	-	0	0	8	24	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Tax shares sold to pay for tax withholdings on equity awards
-8	-6	-14	-28	-25	-14	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-219	-63	10,003	2,221	6,685	8,287	-85	21,310	9,354	8,303	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-29	-6	-	-	2	-28	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-7,689	-8,201	-	-	5,471	15,212	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	3	38	9,189	0	6,886	0	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-31	30	-6	-10	7	0	-0	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-7,784	3,242	3,216	-4,661	-4,435	-3,809	-4,395	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Net (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,826	1,948	-5,138	6,596	-5,260	-3,290	-3,863
Supplemental disclosure for cash flow information:
Interest
0	1	-	-	-	-	-	-	-	0	-	-	0	0	-	-	-	-	-	-	-	-
Interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Income taxes
-	-	-	-	-	-	-0	0	0	0	0	0	0	1	-0	0	0	2	-	-	-	-
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Noncash investing and financing transactions:
Issuance of common stock in connection with a contractual agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	55	-	-	-	-
Expiration of warrants
-	-	3,960	-0	0	100	0	0	664	535	0	1,169	80	228	531	431	0	0	-	-	-	-
Amounts accrued for offering costs
-	-	85	-190	-8	313	-	-	-	201	-	-	-	0	-	-	-	-	-	-	-	-
Noncash activity related to the issuance of warrants in-transit
-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	0	-	-	-	-